Every material Form 8-K Nuwellis, Inc. has filed with the SEC since August 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Nuwellis furnished an updated corporate presentation dated August 25, 2026, under Regulation FD, for use in investor communications and conferences. The deck highlights 20% first-half 2026 revenue growth and a second-quarter 2026 gross margin of 76%, compared with 56% in the prior-year period, and says cash runway extends through the second quarter of 2027.
First-half 2026 revenue grew 20% over the prior-year period, per the presentation.
Second-quarter 2026 gross margin was 76%, versus 56% in the prior-year period.
The company says cash runway runs through the second quarter of 2027.
Company anticipates an FDA submission for the Aquadex pediatric label expansion by year-end 2026.
Nuwellis reported second-quarter 2026 net sales of $2.0 million, up 14% from the prior-year quarter, and gross margin of 76% versus 56% a year earlier. The net loss narrowed to $4.8 million from $12.6 million, though it included about $1.7 million of non-cash warrant valuation expense. The company said about $12.7 million in gross proceeds from June and July financings and warrant exercises extends its cash runway through the second quarter of 2027.
Q2 net sales $2.0 million, up 14%; U.S. revenue up 17%
Q2 gross margin 76%, compared with 56% in the prior-year quarter
Q2 net loss $4.8 million, versus $12.6 million; includes about $1.7 million non-cash warrant expense
Cash of $3.9 million at June 30, 2026; about $12.7 million gross raised in June and after quarter-end
Nuwellis, Inc. sold 1,310,890 common shares at $2.59 per share in a registered direct offering, with gross proceeds expected to be about $3.4 million before placement agent fees and expenses. The offering closed on August 3, 2026, and investors also received warrants to buy up to 1,310,890 more shares at $2.59, which adds potential future dilution for existing shareholders.
Registered direct offering of 1,310,890 shares at $2.59 per share, with gross proceeds expected to be about $3.4 million before fees and expenses
Concurrent private placement of warrants to buy up to 1,310,890 shares at $2.59, exercisable immediately with a five-year term from registration effectiveness
Placement agent Ladenburg Thalmann & Co. Inc. receives a cash fee of 9.0% of gross proceeds plus warrants equal to 3.0% of shares issued
Company separately received $3.1 million from warrant exercises tied to its June 2026 public offering, according to the press release
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Nuwellis, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →